Etavopivat A + Etavopivat B + Etavopivat C
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease, Thalassemia
Trial Timeline
Jan 10, 2025 → Dec 30, 2030
NCT ID
NCT06609226About Etavopivat A + Etavopivat B + Etavopivat C
Etavopivat A + Etavopivat B + Etavopivat C is a phase 3 stage product being developed by Novo Nordisk for Sickle Cell Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06609226. Target conditions include Sickle Cell Disease, Thalassemia.
What happened to similar drugs?
4 of 20 similar drugs in Sickle Cell Disease were approved
Approved (4) Terminated (10) Active (7)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06609226 | Phase 3 | Recruiting |
Competing Products
20 competing products in Sickle Cell Disease